Wolfgang Glaesner,Rohn Lee Millican, Jr.,Andrew Mark Vick
申请号：
US12262832
公开号：
US08273854B2
申请日:
2008.10.31
申请国别(地区):
US
年份:
2012
代理人:
摘要：
The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.
